Polycomb Repressive Complex 2 (PRC2) plays a key role in hematopoietic stem and progenitor cell (HSPC) function. Analyses of mouse mutants harboring deletions of core components have implicated PRC2 in fine-tuning multiple pathways that instruct HSPC behavior, yet how PRC2 is targeted to specific genomic loci within HSPCs remains unknown. Here we use shRNA-mediated knockdown to survey the function of PRC2 accessory factors that were defined in ES cells, by testing the competitive reconstitution capacity of transduced murine HSPCs. We find that similar to the phenotype observed upon depletion of core subunit Suz12, depleting Jarid2 enhances the competitive transplantation capacity of both fetal and adult mouse HSPCs. Furthermore, we demonstrate that depletion of JARID2 enhances the in vitro expansion and in vivo reconstitution capacity of human HSPCs. Gene expression profiling revealed common Suz12 and Jarid2 target genes that are enriched for the H3K27me3 mark established by PRC2. These data implicate Jarid2 as an important component of PRC2 that has a central role in coordinating HSPC function.
Introduction
Polycomb repressive complexes are major epigenetic regulators that control multiple aspects of stem cell fate 1 . PRC2 consists of three core polycomb group proteins: Eed, Suz12 and the histone methyltransferase Ezh2 or Ezh1, which catalyze the di-and trimethylation of histone H3 lysine 27 [2] [3] [4] , the latter which is enriched at transcriptionally silent loci 5 . The generic histone chaperone proteins Rbbp4 and Rbbp7 are also often considered core PRC2 components 2, 3 .
The majority of studies regarding the molecular mechanism of PRC2 targeting have been performed in ES cells, where PRC2 represses a number of key developmental regulators to safeguard pluripotency 6, 7 . Although core PRC2 components lack DNA binding ability, in ES cells several accessory factors, including Jarid2 and the mammalian orthologs of the Drosophila Polycomb-like (Pcl) protein, Phf1, Mtf2 and Phf19, are important both for PRC2 recruitment to target genes and modulating its histone methyltransferase activity.
Jarid2 is a catalytically inactive jumonji family histone demethylase that is essential for PRC2 recruitment in ES cells [8] [9] [10] [11] [12] . Jarid2 has ARID DNA binding and zinc finger domains that demonstrate low affinity binding to DNA with a preference for CpG-rich regions, although this alone cannot explain the specificity of its genomic distribution 9, 10 . Jarid2 additionally exhibits nucleosome and lncRNA binding capabilities that promote PRC2 assembly, association with chromatin and stimulation of methyltransferase activity [13] [14] [15] .
The Pcl proteins are also enriched at some PRC2 targets in ES cells, but predominantly form distinct complexes to PRC2-Jarid2 [16] [17] [18] [19] [20] [21] . Pcl proteins bind the active H3K36me3 mark via their Tudor domain thereby recruiting PRC2 to transcriptionally active chromatin [18] [19] [20] [21] . While these ES cell studies have formed the basis for the paradigms of PRC2 accessory factor function, the extent to which they hold true in other cell types, particularly other rare adult stem cell populations, is unknown.
Hematopoietic stem cells (HSCs) are a well-characterized, clinically relevant stem cell population. HSCs generate the full array of mature blood cell types in a tightly regulated
For personal use only. on June 14, 2017 . by guest www.bloodjournal.org From process that balances self-renewal and differentiation, however alterations to PRC2 disrupt this delicate balance. Although somewhat controversial, Ezh2 appears to be important in highly proliferative fetal HSCs, yet dispensable in their adult counterparts 22, 23 . By contrast, Ezh1 is critical for adult HSCs 24 ; Ezh1 knockout results in bone marrow failure, due to Cdkn2a-induced senescence and reduced homing capacity 24 .
Eed knockout leads to adult HSC exhaustion through the disruption of self-renewal, differentiation and apoptosis 22 . Therefore HSCs represent a relevant and interesting population in which to study PRC2 accessory factor function.
While complete loss of PRC2 core components compromises HSPC function and viability, seemingly contradictorily, heterozygous deletion or depletion by shRNAmediated knockdown leads to enhanced progenitor proliferation and contribution in competitive transplantation assays 22, [25] [26] [27] . Therefore, we have surveyed the function of known PRC2 accessory factors in HSPCs, using shRNA-mediated knockdown and competitive reconstitution assays to determine which factors behave similarly to Suz12 knockdown and demonstrate enhanced contribution to all hematopoietic lineages.
We report that similar to Suz12 knockdown, Jarid2/JARID2 knockdown leads to enhanced capacity for transplantation in fetal and adult HSPCs in mouse, and in human cells cultured in vitro or transplanted into recipient mice. Gene expression profiling of knockdown HSPCs revealed that Jarid2 represses a subset of Suz12 targets in this population, suggesting that Jarid2 plays a dose sensitive role as a PRC2 accessory factor in HSPCs.
Methods

Murine knockdown and transplantation assays
Animal studies were approved by the Walter and Eliza Hall Institute Animal Ethics Committee (AEC 2011.027). Gene-specific shRNA sequences (Supplemental Table 1) were designed using the DSIR website (http://biodev.cea.fr/DSIR/DSIR.html) 28 and subcloned into the LMS-GFP or LMP-BFP vectors, adapted from 29 , with selectable markers EGFP or EBFP/puromycin, respectively. Retrovirus production, E14.5 fetal liver The reads were aligned to mm10 using TopHat version 2.0.8 with the --b2-very-sensitive preset, then summarised over exons using featureCounts from the Rsubread package.
Differential analysis was performed using Voom 31 together with Limma 32 on genes with a count per million (cpm) larger than 1 in at least 2 samples. The data is deposited in GEO (GSE60808).
Further methods and reagents are detailed in the Supplemental Material.
Results:
A functional survey of PRC2 accessory factors identifies Jarid2 as a critical regulator of murine hematopoiesis First, we confirmed expression of all candidate PRC2 accessory factors (Rbbp4, Rbbp7, Phf1, Mtf2, Phf19, Jarid2) in FL-derived Lineage -Sca1 + c-Kit + HSPCs (Fig. 1A) . The rarity of long-term HSCs precludes the use of biochemical techniques to identify PRC2
binding partners, so we tested the function of these factors in an in vivo assay of stem cell function. FL cells were transduced with retrovirus containing validated shRNAs (Supplemental Fig. 3A ) to deplete the expression of the candidate PRC2 accessory factors Suz12 knockdown led to enhanced contribution of transduced cells to both lymphoid and myeloid lineages (Fig. 1C) , as expected 26, 27 . Of the six factors assessed, only Jarid2 knockdown induced a similar phenotype (Fig. 1C) , suggesting Jarid2 may act with PRC2 in hematopoiesis. We assessed the contribution of Rbbp4, Rbbp7, Phf1, Mtf2 or Phf19 depleted donor cells to hematopoietic cell populations in the spleen, thymus and BM at 16 weeks post-transplant (data not shown) including the HSPCs (Supplemental Fig. 4 ).
No consistent change to relative contribution to HSPCs by both validated shRNAs for any of these five accessory factors was found, thus we focused on Jarid2. The efficacy of all hairpins was confirmed by RT-qPCR on splenic lymphocytes (Supplemental Fig. 3A) and Jarid2 and Suz12 knockdown confirmed by Western blot on transduced thymocytes, isolated at 16 weeks post-transplant (Supplemental Fig. 3B ).
Depleting Jarid2-interacting H3K9 methyltransferases does not enhance repopulation capacity of FL donor cells 3C) were used in competitive transplantation assays (Fig. 1B) . In contrast to Suz12 or Jarid2 knockdown, H3K9 methyltransferase knockdown cells displayed a reduced relative contribution to all cell lineages analysed in the peripheral blood at 10 weeks posttransplant (Fig. 1D ). These data suggest Jarid2 is not predominantly functioning in concert with H3K9 methyltransferases, and indicate previously uncharacterized roles for these enzymes in hematopoiesis.
Jarid2 knockdown enhances FL-derived donor cell contribution in competitive transplants
We analyzed the relative contribution of Suz12 or Jarid2 knockdown FL cells to hematopoietic cell populations within the thymus, spleen and BM at 6 and 16 weeks posttransplant. We observed increased relative contribution of both Suz12 and Jarid2 knockdown cells to the HSPC compartment from 6 weeks post-transplant ( Fig. 2A ).
Despite this increase, total peripheral blood counts were normal at 6 and 10 weeks post- 
Suz12 or Jarid2 knockdown augments contribution of FL-derived donor cells to the long-term HSC pool
We used the SLAM cell surface markers CD48 and CD150 to delineate the long-term HSCs (LT-HSC), short term HSCs (ST-HSC) and multipotent progenitors (MPP) within the HSPC population (Fig. 2C ) 36 . Within all these sub-populations both Suz12 and Jarid2 knockdown led to an elevated relative contribution, most markedly with Suz12
To confirm that transduced HSCs were capable of maintaining hematopoiesis through serial transplantation, whole BM from recipients of transduced FL cells was injected into lethally irradiated secondary recipients ( Figure 2F ). This is the phenotype by which a Suz12 ENU-induced point mutation was first identified on a sensitized genetic background 26 . Target gene knockdown was maintained in secondary recipients at 16 weeks post-transplant (Supplemental Fig. 3D ).
These data suggest that while Jarid2 has a role in controlling HSPC behavior, as a PRC2 accessory factor the extent of its role may be more specialized compared to that of core PRC2 component Suz12. Furthermore, it appears that Jarid2 has an additional function within the T cell lineage; interesting in light of the JARID2, SUZ12, EED and EZH2 mutations found in acute T lymphoblastic leukemia [37] [38] [39] . Previous studies imply they may also have a distinct dependency on PRC2: fetal HSCs on PRC2-Ezh2 and adult on PRC2-Ezh1 22, 24 . Jarid2 is associated with PRC2-Ezh2, rather than PRC2-Ezh1 in ES cells 11 , and is only required for PRC2-Ezh2 nucleosome binding 13 . Jarid2 has, however, been shown to stimulate the methyltransferase activity of both complexes 13 . Based on these reports plus our secondary transplant data where Suz12
and Jarid2 knockdown donor cells behaved differently, we examined whether Jarid2 knockdown affects adult HSPCs.
We confirmed Jarid2 expression in fetal and adult LT-HSCs, ST-HSCs and MPPs (Fig.   3A ). Jarid2 expression was comparable between fetal and adult LT-HSCs. Transduced adult BM HSPCs were used to reconstitute lethally irradiated recipients and the relative contribution of Suz12 or Jarid2 knockdown cells to hematopoiesis analyzed (Fig. 3B ).
Both Suz12 and Jarid2 knockdown resulted in enhanced contribution to all cell types examined at early time-points in the peripheral blood ( Fig. 3C ) and at 16 weeks posttransplant in the thymus, spleen and BM (Fig. 3D) . Again, the most pronounced effect of Jarid2 knockdown was within the T cell lineage (Fig. 3D ). Target gene knockdown was confirmed in transduced BM cells isolated at 16 weeks post-transplant (Supplemental Fig. 3E ). These data suggest that, like Suz12, Jarid2 plays a pivotal role in restraining both fetal and adult HSPC repopulation capacity. This may be due to an increased proliferative burden induced by in vitro culture and/or reconstitution that leads to an increased dependence of PRC2-Ezh2 and thus Jarid2 in adult HSPCs.
JARID2 knockdown enhances human HSPC expansion in vitro and in vivo
We next tested whether JARID2 has a role in human HSCs. JARID2 expression was detected in HSPC populations isolated from human cord blood, which contains a mixture of fetal and adult cell types ( 
Jarid2 and Suz12 share common H3K27me3-enriched target genes in HSPCs
We next investigated the molecular effects of Jarid2 knockdown in murine HSPCs. The gene expression profiles of Suz12 and Jarid2 knockdown HSPCs isolated from primary recipients of transduced FL cells at 16 weeks post-transplant were compared to the equivalent negative controls. Suz12 and Jarid2 transcripts were reduced to half that of control samples (Fig. 5A & B) ; however depletion of Jarid2 or Suz12 did not alter transcript levels of PRC2 core components (Fig. 5A ), other accessory factors (Fig. 5B ) or other jumonji domain proteins (data not shown).
In ES cells, Suz12 and Jarid2 share common targets 8, 10, 12 . In HSPCs, 529 genes were differentially expressed between Suz12 knockdown and negative controls (FDR<0.05, Supplemental Table 4 ), 78% of which were up-regulated (Supplemental Fig. 7A & B) .
Jarid2 knockdown (shRNA-Jarid2.1 and shRNA-Jarid2.2 grouped) had a more muted Fig. 7C & D) . While 14 genes were significantly up-regulated in both comparisons, a simple overlap test is biased due to each knockdown being compared with the same control samples and because highly expressed genes have increased power to detect differential expression 42 . Therefore to study the correlation between the effect of the knockdowns in an unbiased manner, we firstly split the control samples between the two comparisons. Secondly we selected genes with evidence of differential expression in both comparison (p<0.01, Fisher's method of combining p-values) and finally we compared the log 2 fold-change between the Jarid2 and Suz12 comparisons. Genes upregulated in the Suz12 knockdown were significantly up-regulated in the Jarid2 knockdown compared with genes that were down-regulated in the Suz12 knockdown (p<10 -5 , Mann Whitney test, Fig. 5C ). This suggests there are common targets of Jarid2 and Suz12.
We contemplated the biological significance of the differentially expressed genes. Both
Lin28b and Hmga2, genes important for the high self-renewal of fetal compared with adult HSCs
43
, were significantly up-regulated in Suz12 knockdown HSPCs (Supplemental Table 4 ). GSEA demonstrated that both Jarid2 and Suz12 knockdown produce a significant up-regulation of genes expressed in fetal HSCs 44 ( Fig. 5D ),
suggesting Jarid2-PRC2 is responsible for repressing the fetal HSC expression signature.
We broadened our analysis to a further 15 hematopoietic gene sets and found a significant enrichment for genes up-regulated in HSCs compared with other hematopoietic cells in both Suz12 and Jarid2 knockdown HSPCs (Supplemental Table 6 ).
Furthermore, an LT-HSC specific gene signature 45 was significantly and strongly upregulated in Suz12 knockdown HSPCs, and modestly up-regulated upon Jarid2 knockdown (FDR q=0.061, Fig. 5E ). These effects had strong signals (Supplemental Table 6 ) and were driven by alteration in expression of different groups of genes (data not shown), shown by leading edge analysis.
We examined whether genes up-regulated in Suz12 or Jarid2 knockdown HSPCs were H3K27me3 marked using published chromatin immunoprecipitation followed by next
sequencing (ChIP-seq) data generated from wild-type adult BM HSPCs 46 and our own ChIP-seq data from E14.5 FL HSPCs (Fig. 6A & B) . Genes repressed by Suz12
and Jarid2 (positive log2-fold change, p<0.01) showed significant H3K27me3 enrichment in adult (Fig. 6A & B) and fetal HSPCs (Fig. 6A) . These genes are likely direct PRC2 targets that are sensitive to reduced Suz12 and/or Jarid2 expression.
To investigate whether Jarid2 and Suz12 directly interact in hematopoetic progenitors, we performed co-immunoprecipitation assays in an ES cell-derived hematopoietic progenitor cell line, HPC7, that can partially sustain hematopoiesis when transplanted into lethally irradiated recipient mice 47 .
Immunoprecipitation of Suz12 pulled down Jarid2 (Supplemental Fig. 8A ), an interaction that was validated by the reverse immunoprecipitation (Supplemental Fig. 8B ). This confirms Jarid2 binds PRC2 in a relevant hematopoietic progenitor population. Furthermore, we found Suz12 knockdown depleted Jarid2 in transduced thymocytes isolated 16 weeks post-transplant (Supplemental Fig. 3B ). Since Suz12 is required for complex stability 48 , this suggests Jarid2 is also part of PRC2 in thymocytes.
Discussion
Here, we investigated the role of PRC2 accessory factors in HSPCs using sensitive, dosedependent competitive reconstitution assays. Of the factors examined, only knockdown of Jarid2 altered the reconstitution capacity of transduced cells. In both FL and BM HSPC primary transplant recipients, depleting Jarid2 mirrored the phenotype observed upon knockdown of PRC2 core component Suz12; both knockdowns increased contribution to the HSC compartment, compared with the negative control. Furthermore, JARID2 knockdown in human cord blood, FL and adult BM CD34 + cells enhanced their capacity to be cultured in vitro, and augmented the contribution of HSC-enriched cord blood cells to transplant recipient mice. These data indicate Jarid2/JARID2 is a newly characterized regulator of HSPC function in mice and humans.
The function of Jarid2 in HSC activity has previously been examined in an RNAi screen targeting Jumonji domain-containing methyltransferases 49 .
Although two unvalidated
For personal use only. on June 14, 2017. by guest www.bloodjournal.org From Jarid2 targeting hairpins scored in their assay, which is similar to ours, Jarid2 was not selected for further study. Mice carrying Jarid2 (Jmj) gene trap alleles have also been used to investigate hematopoiesis; however transplantation assays were qualitative so does not contradict our observation of enhanced contribution by Jarid2 knockdown cells 50 .
While Jarid2 was the only PRC2 accessory factor to influence hematopoiesis in our For personal use only. on June 14, 2017. by guest www.bloodjournal.org From While there was overlap in Jarid2 and Suz12 regulated genes, there were also Suz12 regulated genes not affected by Jarid2 knockdown. This suggests that Jarid2 may be present in only a proportion of PRC2 complexes within HSCs and therefore not affect all aspects of PRC2 function observed with Suz12 knockdown. Alternatively, a reduced level of an accessory factor may have less impact on complex stability or absolute activity than depletion of a core component. Certainly, the contribution of Suz12 knockdown cells to the HSPC compartment, particularly the LT-HSC population, was greater than that observed for Jarid2 knockdown, despite a significant enhancement compared to the negative control. The more muted effect of Jarid2 depletion on HSPC behavior and gene expression in primary recipients may account for the differing phenotypic outcome between Suz12 and Jarid2 knockdown in secondary recipients; a small enrichment of Jarid2 depleted cells may be too small to be observed above the high variance inherent in competitive transplantation. Alternatively, Jarid2 knockdown may even result in mild exhaustion of the HSPCs in secondary recipients, again with a small effect size making it indistinguishably different from controls.
Our study has identified Jarid2/JARID2 as a regulator of HSC function, and highlights JARID2 as a potential therapeutic target for HSC manipulation. Our data suggest that Jarid2 performs this role via interaction with PRC2, providing insight into the mechanistic basis of PRC2 targeting in HSPCs and broadening our understanding of the circumstances in which Jarid2 behaves as a PRC2 component. Interestingly, depletion of PRC2 has different cellular and gene expression outcomes compared to deletion of PRC2 core component Eed 22 . It is worth considering these differing phenotypes in the context of inhibitors that target EZH2 52 , where activity is likely to be reduced but not eliminated.
Additionally, accessory factors and non-enzymatic components of these complexes are emerging as promising therapeutic targets 53,54 so these differing phenotypes may be informative regarding how such drugs, when administered systemically, may affect HSC behavior. In the future it will be interesting to determine whether deletion of Jarid2 in
HSCs has a similar effect to depletion. ).
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